Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Mega Cap Growth ETF (MGK) vs ResMed Inc. (RMD) Price & Performance

Vanguard Mega Cap Growth ETFTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Vanguard Mega Cap Growth ETF vs ResMed Inc. — how do they compare? Vanguard Mega Cap Growth ETF trades at $90.24, while ResMed Inc. trades at $225.9 (market cap $32.61B). The key difference: ResMed Inc. pays a 1.17% dividend while Vanguard Mega Cap Growth ETF pays none, and Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.

MGKRMD
Sector
Broad Market / FactorHealth
52-Week High
$92.06$293.73
52-Week Low
$70.70$182.82
Market Cap
$32.61B
Enterprise Value
$31.97B
Dividend Yield
1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Mega Cap Growth ETF

MGK trades at $90.30, down 0.36% on the day, with technical indicators showing a bullish trend supported by moving averages but overbought RSI readings. The ETF maintains strong institutional interest, with Bay Colony Advisory Group increasing its stake by 378.7% in the latest quarter. Recent news highlights MGK's superior five-year returns compared to small-cap alternatives, though with higher volatility due to its concentrated mega-cap tech focus.

MGK offers exposure to large-cap growth stocks with a low 0.05% expense ratio, delivering strong historical performance but facing concentration risk in technology sectors. The ETF's outlook remains positive given its track record of beating the S&P 500, though investors should monitor tech sector volatility and potential valuation pressures in mega-cap names.

ResMed Inc.

ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.

The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.

Returns comparison

Trailing returns across standard periods

About Vanguard Mega Cap Growth ETF

MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.

Read more on MGK

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD